# C4 Therapeutics (United States)

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/c4-therapeutics-united-states/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 56.5 |
| Citations | 13,625 |
| City | Watertown |
| Country | US |
| Description | C4 Therapeutics (United States) is a research organisation in Watertown, US. OpenAlex records 247 works and 13,625 citations for it. 415 researchers list it as their most recent affiliation. |
| Homepage | http://c4therapeutics.com/ |
| OpenAlex ID | https://openalex.org/I4210153832 |
| Region | Massachusetts |
| Researchers | 415 |
| ROR ID | https://ror.org/05334he48 |
| Type | company |
| Works | 247 |

## University papers

Showing 12 of 18.

- [ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma](https://scholariq.org/papers/esgo-estro-esp-guidelines-for-the-management-of-patients-with-endometrial/)
- [Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial](https://scholariq.org/papers/bevacizumab-combined-with-chemotherapy-for-platinum-resistant-recurrent-ovarian/)
- [Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose](https://scholariq.org/papers/cetuximab-induced-anaphylaxis-and-ige-specific-for-galactose-1-3-galactose/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer-diagnosis-treatment/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial](https://scholariq.org/papers/standard-chemotherapy-with-or-without-bevacizumab-for-women-with-newly-diagnosed/)
- [Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer](https://scholariq.org/papers/dostarlimab-for-primary-advanced-or-recurrent-endometrial-cancer/)
- [ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer](https://scholariq.org/papers/esmo-esgo-estro-consensus-conference-on-endometrial-cancer/)
- [Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/endometrial-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.](https://scholariq.org/papers/epidermal-growth-factor-receptor-blockade-with-c225-plus-gemcitabine-results-in/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [The forefront of ovarian cancer therapy: update on PARP inhibitors](https://scholariq.org/papers/the-forefront-of-ovarian-cancer-therapy-update-on-parp-inhibitors/)

## University researchers

- [Mansoor Raza Mirza](https://scholariq.org/researchers/mansoor-raza-mirza/)

## University top topics

Showing 8 of 25.

- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Ubiquitin and proteasome pathways](https://scholariq.org/topics/ubiquitin-and-proteasome-pathways/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [RNA modifications and cancer](https://scholariq.org/topics/rna-modifications-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.